N-alkyl-nitrosoureas and alkyl-triazenes are alkylating antineoplastic drugs, the efficacy of which is strongly affected by the level of expression of the DNA-repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT). In tumors, MGMT activity reduces the chemotherapeutic potential of alkylating drugs; therefore, efforts have been made to down-regulate the protein. A partial sensitization of Mex ϩ cells to alkylating drugs has been obtained using either free alkylated bases or oligonucleotides targeted against MGMT mRNA. In the present work, O 6 -methylguanine and a chemically modified ribozyme, without a cationic liposome as a carrier, were coadministered to CHO47 cells, which express a high level of human MGMT protein. The reduction of MGMT mRNA and protein enhanced the genotoxicity of the alkylating drug mitozolomide. Furthermore, the sensitivity of CHO47 cells is the same as that of CHO5 cells, which lack MGMT protein. These data indicate that a strategy in which both mRNA and protein are degradation targets can be successfully applied to down-regulate the MGMT gene. Cancer Gene Therapy (2000) 7, 905-909
T he Mex
ϩ phenotype defines a cell that expresses the O 6 -methylguanine (MeG)-DNA methyltransferase (MGMT) repair enzyme. The protein is able to repair DNA alkylation damage by transferring the alkyl group from the O 6 position of guanine to a catalytic cysteine residue in a stoichiometric reaction. 1 Because a high level of expression of the MGMT gene was observed in human tumors resistant to alkylating antineoplastic drugs such as N-alkyl-nitrosoureas and alkyl-triazenes, 2, 3 down-regulation of the MGMT gene represents a possible strategy to bypass the resistance. A peculiarity of the repair protein is that each molecule that has reacted with either a free O 6 alkylated guanine or an alkylated base in DNA is inactivated and degraded. 4 -6 Therefore, pretreatment with an alkylated base such as benzylguanine or methylguanine provides a means to deplete MGMT protein and thus renders the tumor cells sensitive to lower doses of chemotherapeutic alkylating drugs. 7, 8 We found, however, that the alkylating drug mitozolomide (MTZ) was less cytotoxic to Mex ϩ cells depleted of MGMT than to Mex Ϫ cells, which do not have MGMT activity. 9 This indicates that despite MGMT depletion, the cells retained the Mex ϩ phenotype. An alternative approach uses oligonucleotides such as antisense oligodeoxynucleotides 10 and hammerhead ribozymes 11 to
cleave MGMT mRNA and potentiates the genotoxicity of MTZ while cells are still Mex ϩ . It seems that neither alkylated base nor oligonucleotides are independently adequate to sensitize Mex ϩ cells fully to alkylating drugs. Most likely, the very long half-life of MGMT mRNA 12 as well as the incomplete inactivation of the MGMT protein pool 9 influence the maintenance of the Mex ϩ phenotype. To test this hypothesis, we coadministered ribozyme and MeG to CHO47-transfected cell lines in which the expression of human MGMT and correlations with sister chromatid exchanges (SCEs) and other genetic endpoints have been largely investigated and described. 10, 13 Here, we report that such dual treatment was able to sensitize Mex ϩ cells.
MATERIALS AND METHODS

Ribozymes
The hammerhead ribozyme Rz-MT2 targeted against the GUU triplet located in region 737-749 of MGMT mRNA (GenBank accession number M29971) and its modified forms, Rz-MT2E and Rz-MT2Ei, have been characterized previously 11 and are shown in Figure 1 . The ribozymes and short substrate sequences were chemically synthesized according to a method described previously. 14, 15 Their activities were assessed by in vitro cleavage of a 13-mer synthetic substrate under multiple turnover conditions. Cleavage rates were quantified by high-performance liquid chromatography analysis. 16 
mRNA cleavage
MGMT full-length mRNA was obtained by in vitro transcription. The plasmid pG3AT 835, which contains an 835-bp MGMT cDNA fragment downstream of a T7 RNA polymerase binding site, was linearized by BamHI digestion and transcribed using an Ampliscribe T7 RNA polymerase kit (Epicentre Technologies, Madison, Wis) according to the manufacturer's recommended protocol. The cleavage assay was done under single turnover conditions using 40 M ribozyme and 1.6 M substrate mRNA. Mixtures were incubated at 50°C in the presence of 10 mM MgCl 2 . Sample timepoints were collected, mixed with loading buffer, and loaded in 2% agarose gel. Cleavage products were then visualized by ethidium bromide (EB) staining.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from 10 6 cells. 11 A total of 6 g of RNA was transcribed at 42°C for 1 hour with 4 U of avian myeloblastosis virus reverse transcriptase (Roche Diagnostics, Milan, Italy) in a 40-L reaction mixture containing 40 U of ribonuclease inhibitor, 8 L of 5ϫ transcription buffer, 5.0 M random hexamers, and 1 M of each deoxynucleoside triphosphate. A 299-bp MGMT cDNA fragment containing the cleavage site of Rz-MT2 ribozyme was then amplified by PCR in a 50-L reaction containing 12 L of the reverse transcriptase mixture, 5 L of 10ϫ PCR buffer, 5 mM MgCl 2 , 2 mM deoxynucleoside triphosphate, 8 U of Taq polymerase (Roche IT), and 1 M of both forward (5Ј-CGAGCAGTGGGAG-GAGCA-3Ј) and reverse (5Ј-CATCCGATGCAGTGTTA-CACG-3Ј) primers. PCR conditions were as follows: denaturation at 94°C for 5 minutes for the first cycle and 1 minute for the following cycles, annealing at 58°C for 1 minute, and extension at 72°C for 2 minutes. As an internal standard, a 552-bp cDNA fragment of the hamster hypoxanthine phosphoribosyl transferase (HPRT) gene was coamplified with 5Ј-CAGATTCAACTTGAACTCTC-3Ј and 5Ј-AAAGGTGTT-TATTCCTCATGGA-3Ј as forward and reverse primers, respectively. The PCR products were separated on a 1.0% agarose gel and visualized with EB staining.
Immunoblotting
The immunoblotting procedure has been described previously. 9 Briefly, samples consisting of 5 ϫ 10 5 cells were lysed in ice-cold lysis buffer for 30 minutes and centrifuged at 10,000 rpm for 10 minutes. Next, 30 g of protein from each sample was separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (200 V constant voltage) and transferred electrophoretically onto a nitrocellulose membrane. After blocking with a 5% solution dry milk in tris(hydroxymethyl) aminomethane-buffered saline-Tween 20, the membrane was incubated for 1 hour with a monoclonal anti-MGMT antibody, 3B8 (Applied Genetics, Freeport, NY), followed by peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, Calif). Blots were developed by enhanced chemiluminescence (Amersham, Arlington Heights, Ill), and the subsequent radiographic signals were quantified by densitometric analysis using Gel-base software (UVP video-image recorder/analysis; Ultraviolet Products, St. Gabriel, Calif). To normalize for protein loading, the membrane was stripped, reprobed for 1 hour for actin, and processed as described above.
Cell line and treatment procedures
The CHO-TK47-AT17-C3 (CHO47) cell line transfected with neo gene and human MGMT cDNA and the CHO5 cell line Figure 1 . Sequences of Rz-MT2, Rz-MT2E, and Rz-MT2Ei ribozymes. Rz-MT2E contained one and two phosphorothioates at the 5Ј and 3Ј ends, respectively. All pyrimidine nucleotides were replaced by 2Ј-fluorocytidine (C F ), 2Ј-fluorouridine (U F ), and 2Ј-amino-uridine (U NH2 ) in the core. Rz-MT2Ei has the same modifications as Rz-MT2E, but the substrate binding arms were inverted to prevent such binding. Asterisks indicate the phosphorothioates; numbering is according to Hertel et al. 18 transfected with neo gene 13 were cultured in 1:1 Dulbecco's modified Eagle's medium:␣-minimal essential medium supplemented with 1.5 mg/mL G418 and 10% heat-inactivated (30 minutes at 56°C) fetal calf sera at 37°C in a humidified atmosphere containing 6% CO 2 . Under these conditions, CHO47 cells express 97,000 molecules of MGMT per cell, whereas CHO5 cells were devoid of any activity. CHO47 cells were seeded in a 24-well dish at 5 ϫ 10 4 cells/well and grown in the absence (Ϫ) or presence (ϩ) of 600 M MeG. During concurrent administrations, 400 L of complete medium containing 10 M Rz-MT2E and 600 M MeG was administered to each well; next, wells were incubated for 24 hours. Both Rz-MT2E and Rz-MT2Ei were readministered once during the 24 hours of treatment. Thereafter, cells were treated for 1 hour with 10 g/mL of the alkylating agent MTZ solubilized in dimethylsulfoxide.
Genotoxicity
The genotoxic effect of MTZ was monitored at the chromosomal level by measuring the induction of SCEs, which is inversely related to MGMT activity. 10 After MTZ treatment, cells were grown for two cell cycles (24 -26 hours) in medium containing 3 g/mL bromodeoxyuridine. Afterward, cells were incubated in 0.05 g/mL colcemid for 1.5 hours, collected by trypsinization, and fixed with a 3:1 mixture of methanol:acetic acid. Preparation and fluorescence plus Giemsa staining of slides were done according to a standard procedure. 17 SCEs of at least 15 metaphases were counted for each experimental point.
RESULTS
We have shown previously that Rz-MT2 ribozyme and its modified form, Rz-MT2E, are able to cleave short MGMT synthetic substrates; in addition, Rz-MT2E has an extended stability in culture medium. 11 Here, we test their cleavage activity on full-length MGMT mRNA. Through electrophoretic monitoring of single turnover reactions (Fig 2A) , we were able to demonstrate the specific cleavage of target RNA because all components of reaction were detected: mRNA substrate of 835 nucleotides (nt), cleavage product 1 of 743 nt, cleavage product 2 of 92 nt, and synthetic ribozyme of 34 nt. The chemical modifications introduced into Rz-MT2E slightly delayed the progression of cleavage. These results confirm that chemical stabilization reduces the cleavage activity of ribozymes. 14, 15 Nevertheless, a nonspecific degradation of RNAs during the long cleavage incubation time was also observed (Fig 2B) .
The effects of Rz-MT2E ribozyme on MGMT protein level are shown in Figure 3 . At 24 hours after the administration of Rz-MT2E and MeG, the amount of immunoreactive MGMT protein decreased by 74% (Fig  3, lane 4 ) compared with control extract (Fig 3, lane 1) . A reduction of 27% and 20% was also observed after treatment with MeG and Rz-MT2E, respectively (Fig 3,  lanes 2 and 6) . The effect seems to be specific, because administration of the inactive ribozyme Rz-MT2Ei did not decrease the immunoreactive protein levels regardless of whether MeG was coadministered (32%; Fig 3,  lane 3) or not (Ͻ1%; Fig 3, lane 5) . These results clearly indicate that the resynthesis of MGMT protein was inhibited in a Rz-MT2E ribozyme-dependent manner.
Our observations were confirmed by RT-PCR of total RNA extracted 24 hours after coadministration of Rz-MT2E and MeG (Fig 4) . For our analysis, we used two primer pairs complementary to MGMT and HPRT. The basis of such a comparative analysis is that the two genes will compete with each other during PCR. Any change in the mRNA amount of one gene will affect the amount of PCR product as result of preferential amplification of the other gene. We observed that the signal intensity of the MGMT fragment of CHO47 cells was more intense than that of the HPRT fragment (Fig 4, lane 1) . Similar results were observed when CHO47 cells were incubated with Rz-MT2Ei ribozyme (Fig 4, lane 2) . Conversely, incubation with Rz-MT2E reduced the signal intensity of the MGMT fragment. Concomitantly, an increase in the HPRT fragment was seen (Fig 4, lane 3) . Hence, the level of MGMT protein reflects the quantity of its mRNA.
We subsequently studied how a reduction in MGMT activity affected the induction of SCEs (Table 1) . We observed that additional SCEs (⌬SCE) were significantly induced by both separate and concomitant exposure of CHO47 cells to MeG and Rz-MT2E. The enhancement per cell over the control level is specific because treatment with Rz-MT2Ei inactive ribozyme insignificantly increased the frequency of SCEs per cell. These data are in agreement with those obtained after the administration of the same ribozymes with the transfection reagent
To evaluate whether the sensitization reached by CHO47 cells was due to the depletion of MGMT protein, CHO5 cells, which are devoid of MGMT protein, were challenged with MTZ. We observed that SCEs were enhanced at level that was comparable with that of CHO47 cells exposed to MeG and Rz-MT2E (Table 1) . Moreover, neither exposure to MeG nor exposure to Rz-MT2E significantly affected the SCE induction in CHO5 cells. Figure 5 compares the sensitization of CHO47 cells to MTZ resulting from the administration of MeG and Rz-MT2E either separately or jointly. It can be noted that the best result (3.84-fold increase) was obtained when CHO47 cells were exposed to both molecules.
DISCUSSION
In this work, we down-regulate MGMT protein by acting concurrently at the levels of mRNA translation and protein. This dual approach was chosen because the individual treatments of either mRNA cleavage via oligonucleotides or protein degradation via free alkylated base could not effectively sensitize cells overexpressing MGMT protein to alkylating drugs. Reduction of mRNA levels was facilitated tremendously by the availability of Rz-MT2E ribozyme, which is active both in vitro and in vivo and, mostly importantly, is stable in culture medium. 11 These features removed the need for transfection reagents and allowed exposures to last up to 24 hours and the study of variations at later timepoints. A reduction in both MGMT mRNA and protein was always observed when Rz-MT2E ribozyme was used, confirming ribozyme specificity. We have previously shown an inverse correlation between SCE frequency and active MGMT content, 10, 13 and so we monitored the sensitization of CHO47 cells to MTZ using this endpoint. Treatment with Rz-MT2E or MeG resulted in an increased MTZ genotoxicity; this was reflected in a respective SCE increase of 34% (6.7/19.5) and 56% (11/19.5) above the control cell baseline. When both Rz-MT2E and MeG were coadministered, the genotoxicity of MTZ increased that of Mex Ϫ cells. In untreated cells, the MGMT protein is located prevalently in the cytoplasm (Ͼ90%), 9 where it persists as an active protein for several hours. Upon MeG treatment, protein is inactivated within 1 hour, and a steady-state equilibrium between the free and active MGMT and that bound to MeG is established. 9 In this work, we observed a detectable reduction of MGMT protein in Rz-MT2E treated cells. We believe that this reduction results from the contributions of Rz-MT2E to the depletion process of MGMT protein. Upon MeG treatment, nuclear MGMT has been reported to be present at one-fifth of the abundance of cytoplasmic MGMT. 9 This suggests that protein, which has reacted with MeG, is degraded more rapidly within the nucleus than the cytoplasm. The elevated levels of DNA damaged due to coadministration of Rz-MT2E and MeG over that caused by individual treatments clearly indicates differing MGMT concentrations in the nuclei. In addition, the demonstration that the number of SCEs per Mex ϩ cell after dual treatment approached the levels seen in Mex Ϫ CHO5 cells indirectly suggests the absence of MGMT protein in the nuclei of CHO47 cells. Hence, the sensitization of Mex ϩ cells to alkylating drugs depends upon mRNA and protein degradation kinetics. The occurrence of both renders CHO47 cells, which overexpress MGMT, sensitive to the alkylating drugs to the extent of CHO5 cells, which are devoid of the repair protein.
In conclusion, we present a strategy that down-regulates a given gene function but that must be designed for each gene. For some genes, mRNA offers a better target than the gene product or vice versa. Lastly, other genes may require both mRNA and the corresponding protein to be considered as targets. The MGMT gene acts as a paradigm of specific down-regulation when both MGMT mRNA and protein are degradation targets.
